Related Experiment Videos
The cardiac and vascular effects of lacidipine
1Cattedra di Semeiotica e Metodologia Medica, University of Brescia, Italy.
Insights
Lacidipine demonstrates vasoprotective effects, maintaining vital organ perfusion and reducing left ventricular hypertrophy. This calcium channel blocker offers vasodilation and improves arterial compliance in essential hypertension.
Area of Science:
- Cardiovascular Pharmacology
- Vascular Medicine
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events.
- Essential hypertension is associated with abnormal arterial compliance and increased media/lumen ratios in resistance arteries.
- Vital organ perfusion can be compromised in hypertensive states.
Purpose of the Study:
- To evaluate the vasoprotective and organ-protective effects of lacidipine.
- To assess lacidipine's impact on left ventricular hypertrophy and cardiac function.
- To investigate lacidipine's influence on arterial structure and compliance in hypertension.
Main Methods:
- Animal studies using spontaneously hypertensive rats.
- Clinical trials in human patients with essential hypertension.
- Assessment of vital organ perfusion, left ventricular structure and function, and arterial compliance.
Main Results:
- Lacidipine administration maintained or increased vital organ perfusion.
- Significant reduction in LVH was observed within 3 months.
- Systolic function remained unchanged, while diastolic function may improve.
- Abnormal arterial compliance in large arteries was reversed.
- Elevated media/lumen ratio in small resistance arteries was reduced.
Conclusions:
- Lacidipine exhibits vascular selectivity, promoting vasodilation.
- The drug effectively reduces LVH and improves arterial properties in hypertension.
- Lacidipine maintains or enhances vital organ perfusion, highlighting its therapeutic potential.
Abstract:
The vasoprotective activity of lacidipine has been demonstrated both in animals and humans. Results from several studies indicate that vital organ perfusion is maintained, or even increased, during lacidipine administration. Left ventricular hypertrophy (LVH) represents an independent risk factor for cardiovascular events. Lacidipine has been shown to reduce LVH significantly within 3 months of initiation of treatment. In addition, systolic function, as evaluated by ejection fraction and fractional shortening of the left ventricle, is unchanged after 6 months of treatment with lacidipine. Diastolic function may also be improved by this treatment. In large arteries, lacidipine can reverse the abnormal arterial compliance observed in patients with essential hypertension. Other studies, in spontaneously hypertensive rats, have shown that lacidipine can significantly reduce the elevated media/lumen ratio of small resistance arteries. In conclusion, lacidipine possesses vascular selectivity and its effect in essential hypertension is characterized by vasodilation and by the maintenance, or even improvement, in vital organ perfusion.